AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06636864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
Study NCT05166811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate, Heptahydrate
Description: A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
Study NCT05166811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
Study NCT06084104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: A single oral dose of 200mg DZD9008
Study NCT06129760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: The wearable sensor device is the Apple Watch Series 6 or newer
Study NCT05771194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine preoperative and postoperative anti-infection therapy
Description: received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
Study NCT05771194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine preoperative and postoperative anti-infection therapy
Description: received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
Study NCT05771194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tear therapy
Description: given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
Study NCT05771194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning, hot compresses and massage of the meibomian gland
Description: Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
Study NCT06689969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseodensification to implant placement using densah bur kit
Description: Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order
Study NCT05274347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muti-faceted virtual, remote intervention
Description: Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
Study NCT06118775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EaDyn Weaning Arm:
Description: The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.
Study NCT06118775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAM Weaning Arm:
Description: The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
Study NCT05447962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Description: Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
Study NCT05447962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)
Description: Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
Study NCT05447962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barbershop-Based Facilitation (BF)
Description: Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
Study NCT04103372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
Study NCT04103372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiologist training
Description: Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
Study NCT06513429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells by intravenous infusion.
Study NCT05043610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)
Description: cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
Study NCT05043610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
Study NCT05043610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
Study NCT06027086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
Study NCT06027086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
Study NCT04652258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Actemra
Description: Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
Study NCT05321953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Care
Description: Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
Study NCT05321953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy Care
Description: Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
Study NCT05321953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Inspiratory Muscle Training
Description: The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
Study NCT06396481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cell
Description: The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
Study NCT05444504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cup
Description: an insertable vaginal cup ('cup')
Study NCT05444504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cup+
Description: the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
Study NCT05932810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT05932810 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
Study NCT06351410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Wearing Contact Lens
Description: Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
Study NCT06302634 — intervention group
Intervention type: OTHER
Intervention: Exercise-based cardio-oncology rehabilitation
Description: Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
Study NCT06510465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
Study NCT06510465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
Study NCT06510465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
Study NCT06510465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
Study NCT05696366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
Study NCT05459714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE for obese patients
Description: Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
Study NCT05696366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Volagidemab
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
Study NCT05696366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volagidemab
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
Study NCT05115201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with antibiotics
Description: Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
Study NCT05115201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing only
Description: Patients will be treated with scaling and root planing
Study NCT05144061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2398 Tablets
Description: Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
Study NCT06483633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT + CPT, HIIT + CPT, SIT + CPT
Description: Single acute intervention, each exercise mode had a washout period of at least 7 days.
Study NCT04325815 — intervention group
Intervention type: DEVICE
Intervention: CADDIE- Computer Aided (AI) Device used in Endoscopy
Description: 1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation
Study NCT06513767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia Dental Ceramics
Description: This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T11
Description: Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T11
Description: Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
Study NCT05153486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
Study NCT05153486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
Study NCT05153486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation
Description: Patients receive surgical ablation.
Study NCT05734872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
Study NCT04729049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae plane Block
Description: Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
Study NCT05734872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine mental health course training
Description: Conduct mental health education for patients by making a speech.
Study NCT06499948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Spironolactone followed by Dapagliflozin followed by their combination
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.